



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Infants with Atypical Presentations of Alveolar Capillary Dysplasia with Misalignment of the Pulmonary Veins Who Underwent Bilateral Lung Transplantation

Christopher T. Towe, MD¹, Frances V. White, MD², R. Mark Grady, MD³, Stuart C. Sweet, MD, PhD³, Pirooz Eghtesady, MD, PhD⁴, Daniel J. Wegner, MS³, Partha Sen, PhD⁵, Przemyslaw Szafranski, PhD⁵, Pawel Stankiewicz, PhD⁵, Aaron Hamvas, MD⁶, F. Sessions Cole, MD³, and Jennifer A. Wambach, MD, MS³

Objective To describe disease course, histopathology, and outcomes for infants with atypical presentations of alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV) who underwent bilateral lung transplantation.

Study design We reviewed clinical history, diagnostic studies, explant histology, genetic sequence results, and post-transplant course for 6 infants with atypical ACDMPV who underwent bilateral lung transplantation at St. Louis Children's Hospital. We compared their histology with infants with classic ACDMPV and compared their outcomes with infants transplanted for other indications.

Results In contrast with neonates with classic ACDMPV who present with severe hypoxemia and refractory pulmonary hypertension within hours of birth, none of the infants with atypical ACDMPV presented with progressive neonatal respiratory failure. Three infants had mild neonatal respiratory distress and received nasal cannula oxygen. Three other infants had no respiratory symptoms at birth and presented with hypoxemia and pulmonary hypertension at 2-3 months of age. Bilateral lung transplantation was performed at 4-20 months of age. Unlike in classic ACDMPV, histopathologic findings were not distributed uniformly and were not diffuse. Three subjects had apparent nonmosaic genetic defects involving *FOXF1*. Two infants had extrapulmonary anomalies (posterior urethral valves, inguinal hernia). Three transplanted children are alive at 5-16 years of age, similar to outcomes for infants transplanted for other indications. Lung explants from infants with atypical ACDMPV demonstrated diagnostic but non-uniform histopathologic findings.

Conclusions The 1- and 5-year survival rates for infants with atypical ACDMPV are similar to infants transplanted for other indications. Given the clinical and histopathologic spectra, ACDMPV should be considered in infants with hypoxemia and pulmonary hypertension, even beyond the newborn period. (*J Pediatr* 2018;194:158-64).

Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV, OMIM 265380) is a rare developmental lung disorder with nearly uniform mortality in the first month of life.^{1,2} Neonates with classic ACDMPV are typically born at term and present with progressive, hypoxemic respiratory failure and severe, refractory pulmonary hypertension within the first few hours after birth. Extrapulmonary anomalies are common and typically involve the gastrointestinal, cardiac, and/or genitourinary systems.³ Although there are a few case reports of infants with atypical presentations of ACDMPV beyond the newborn period or with less fulminant neonatal disease⁴⁻⁹ (Table I; available at www.jpeds.com), the clinical, histopathologic, and genetic factors that contribute to delayed or less severe presentations are not well-characterized.

The diagnosis of ACDMPV is made by histologic examination of lung tissue.¹⁰ Owing to the high neonatal mortality rate, many infants are diagnosed at autopsy, although a steady increase in diagnosis by lung biopsy has recently been observed.³ The histopathologic features diagnostic of ACDMPV include deficient capillarization

ACDMPV	Alveolar capillary dysplasia with misalignment of the pulmonary veins
BVB	Bronchovascular bundle
CNV	Copy number variant
CT	Computed tomography
DOL	Day of life
FEV ₁	Forced expiratory volume in 1 second
FVC	Forced vital capacity
ILD	Interstitial lung disease
RV	Residual volume
TLC	Total lung capacity

From the ¹Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ²Department of Pathology and Immunology; ³Edward Mallinckrodt Department of Pediatrics; ⁴Department of Surgery, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO; ⁵Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; and ⁶Department of Pediatrics, Northwestern University Feinberg School of Medicine Chicago, IL

Supported by the National Institutes of Health (T32 HL007873 [C.T.], K08 HL105891 [J.W.], K12 HL120002 [F.C.], R01 HL065174 [F.C.], R21/R33 HL120760 [F.C.]), R01 HL137203 and HL101975 (P.St.), American Lung Association (J.W.), American Thoracic Society (J.W.), Children's Discovery Institute (CDI-LI-2014-428 and CDI-LI-2016-569 [F.C. and J.W.]), and National Organization for Rare Disorders (NORD 2016) (P.Sz.)

0022-3476/\$ - see front matter. © 2017 Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.jpeds.2017.10.026>

of the alveoli (decreased numbers of capillaries with displacement from alveolar epithelium), malposition of pulmonary veins adjacent to small pulmonary arteries within the same bronchovascular bundle (BVB), and medial hypertrophy of small pulmonary arteries and arterioles. Lobular maldevelopment with deficient alveolarization and lymphangiectasis are also commonly observed.^{1,11-13} Although it has been speculated that infants with delayed or less fulminant (atypical) presentations may have nonuniform distribution of disease that does not involve the entire lung, less abnormal density and placement of capillaries, or more normal lobular development,^{5,14,15} limited information regarding the lung histopathology of these infants is available and often from only a single biopsy site.

Although the outcomes after bilateral lung transplant in infants with end-stage lung disease owing to genetic disorders of surfactant metabolism, interstitial lung disease (ILD), and pulmonary vascular disease have been reported,¹⁶ the long-term outcomes of patients transplanted after atypical presentation of ACDMPV presentation have not been reported. Herein we report clinical data and histologic characterization from the largest series of infants with atypical presentations of ACDMPV who underwent lung transplantation.

Methods

Through a search of the St. Louis Children's Hospital/Washington University School of Medicine Pediatric Lung Transplantation database, we identified 6 infants with atypical presentations of ACDMPV admitted over an 18-year period (1998-2016) who underwent bilateral lung transplantation. We obtained informed consent from parents of all infants and children and this study was approved by the Human Research Protection Office at Washington University. We reviewed clinical history, results from echocardiogram, cardiac catheterization, and chest computed tomography (CT), explant histology, and post-transplant course. We used Sanger sequencing to identify mutations in *FOXF1* as described previously.¹⁷ We analyzed genomic copy number variants (CNVs) using array comparative genomic hybridization with custom-designed 16q24.1 region-specific 3_720 K microarrays (Roche NimbleGen, Madison, Wisconsin).¹⁷

A pediatric pathologist with expertise in childhood ILD and the diagnostic features of ACDMPV reviewed all explants. At least 2 sections from each lobe of the explant were reviewed for each subject (median number of sections per explant, 22; range, 12-27). Explant histology was compared with autopsy histology from 3 infants with classic ACDMPV and genetic defects of *FOXF1* (2 with missense point mutations and 1 with a CNV deletion upstream of *FOXF1*). ACDMPV histologic criteria were characterized for each explant.^{15,18} Microscopic observations of alveolar capillaries were made on fields of congested, noncollapsed lung, in which architecture and capillaries were well-visualized. Findings of deficient capillarization of alveoli were described as "diffuse" (present throughout all fields, with difficulty in identifying normal capillarization in most fields), "mixed" (mixture of both normal and deficient

capillarization throughout lung), and "focal" (predominantly normal, with focal areas of deficient capillarization). Findings of pulmonary vein malposition adjacent to small arteries were described as "extensive" (readily identified throughout the lung, with malposition in the majority of BVBs), "patchy" (identified throughout the lung, but in fewer than one-half of BVBs), and "focal" (present, but in a minority of BVBs and not readily identified). Assessment of malposition of pulmonary veins did not include BVBs with tangential orientation in which a vein could not be excluded. Findings of medial hypertrophy of small arteries and arterioles were graded "mild," "moderate," or "severe," ranging from mild medial thickening to occlusive lesions. Lobular maldevelopment with deficient alveolarization was noted based on the presence of enlarged alveoli with apparent decrease in numbers of alveoli and was described as "present," "suggestive" (areas suggestive of deficient alveolarization), or "not suggestive." Lymphangiectasis was characterized as primarily involving the interlobular septae or involving both the interlobular septae and the BVBs.

Infant 1

A term male infant developed tachypnea at birth, was treated with oxygen, and then discharged home on room air (Table II). He was also noted to have an inguinal hernia at birth. During the first few months of life, he experienced several episodes of pulmonary congestion attributed to upper respiratory tract infections before presenting on day of life (DOL) 109 with respiratory distress and severe pulmonary hypertension that required mechanical ventilation, vasopressor support, pulmonary vasodilators, and venoarterial extracorporeal membrane oxygenation for 8 days. He remained mechanically ventilated until bilateral lung transplant on DOL 139. He did well post-transplant for several years before developing bronchiolitis obliterans that led to a second transplant at 5 years of age. Two months after his second transplant, he developed progressive renal failure and died.

Infant 2

A term male infant developed neonatal respiratory distress and was treated with supplemental oxygen and continuous positive airway pressure on DOL 2. An echocardiogram demonstrated pulmonary hypertension. He was also noted to have nonobstructive posterior urethral valves. Owing to persistent oxygen requirement at 1 month of age, he underwent open lung biopsy, which was diagnostic for ACDMPV. At 2 months of age, a cardiac catheterization demonstrated suprasystemic right heart pressures that were mildly responsive to inhaled nitric oxide. He was discharged home on nasal cannula oxygen (0.5 L/minute) and nitric oxide (0.5 L/minute; estimated 5 parts per million). His oxygen and nitric oxide requirements gradually increased, and his pulmonary hypertension worsened, prompting bilateral lung transplantation at 21 months of age. He did well until 4 years of age, when he required a second transplant for chronic lung allograft dysfunction owing to rejection. He is alive at 16 years of age with bronchiolitis obliterans. Most recent (15 years) spirometry revealed forced

Table II. Clinical characteristics of infants with atypical presentation of ACDMPV^{17,19}

Patients	EGA (wks)	Neonatal symptoms	Age at presentation	Cardiac anomalies	Additional anomalies	CT imaging	Cardiac catheterization	Pulmonary hypertension medications	ECMO	Support at time of lung transplantation	Age at transplantation (mo)	Outcome
1	Term	Transient tachypnea at birth, discharged home on room air	3 months (109 days)	None	Inguinal hernia	Not available	Not performed	Prostacyclin, iNO	Before transplant	Mechanical ventilation	4	Second transplant at 4 years of age; died at 5 years of age
2	Term	Respiratory distress, pulmonary hypertension	Birth	Patent foramen ovale	Posterior urethral valves	Ground glass opacities, enlarged pulmonary vessels	Suprasystemic RV pressure, responsive to iNO	Nifedipine, iNO	No	NO and O ₂ via nasal cannula	20	Second transplant at 4 years of age; alive at 16 years of age
3	36	None	2 months (71 days)	Patent foramen ovale	None	Diffuse ILD, associated cystic areas	Not performed	Milrinone, methylprednisolone, iNO	No	Mechanical ventilation	5	Alive at 14 years of age
4	34	Poor feeding, abdominal distension at 3 days	2 months (67 days)	Secundum atrial septal defect	None	Ground glass opacities, interstitial septal thickening	Suprasystemic RV pressure, responsive to iNO	Sildenafil, milrinone, iNO	No	Mechanical ventilation	5	Died at 9 years of age
5	34	Apnea at 3 weeks	3 months (92 days)	Patent foramen ovale	None	Ground glass opacities	Not performed	Sildenafil	At transplant	ECMO	9	Alive at 5 years of age
6	Term	Transient tachypnea, discharged home on O ₂ for 21 days	7 months (212 days)	Patent ductus arteriosus	None	Ground glass opacities with septal thickening	Near systemic RV pressure, responsive to iNO	Sildenafil, methylprednisolone, iNO	Before transplant	Positive pressure ventilation via RAM cannula	15	Died at 18 months of age

ECMO, extracorporeal membrane oxygenation; EGA, Estimated gestational age; iNO, inhaled nitric oxide; RAM, right ventricular.

expiratory volume in 1 second (FEV₁) of 31% predicted, forced vital capacity (FVC) of 40% predicted, and FEV₁/FVC of 68% indicating airflow obstruction (no response in FEV₁ to bronchodilator therapy). Total lung capacity (TLC) was 2.29 L (60% predicted) and the residual volume (RV) was 0.99 L (111% predicted) with an RV/TLC of 43%, indicating air trapping. Diffusing capacity of the lungs for carbon monoxide was 67% predicted.

Infant 3

A female infant born at 36 weeks of gestation had no neonatal respiratory symptoms or congenital anomalies, but had a male sibling who died after lung transplantation for ACDMPV. She presented on DOL 71 with respiratory distress, cyanosis, and pulmonary hypertension by echocardiogram and was treated with mechanical ventilation, vasopressor support, and pulmonary vasodilators. She required mechanical ventilation until undergoing transplantation on DOL 159 and is alive with normal lung function at 14 years of age. Most recent (age 14 years) spirometry was essentially normal (FEV₁ 90% of predicted, FVC 86% of predicted, and FEV₁/FVC 90%). TLC was 4.66 L (110% predicted) and RV was 1.71 L (154% predicted) with an RV/TLC ratio of 37%, suggestive of mild air trapping. The diffusing capacity of the lungs for carbon monoxide was normal.

Infant 4

A late preterm female infant born at 34 weeks of gestation developed abdominal distension and intestinal dysmotility on DOL 3 that resolved during a 17-day hospitalization in the neonatal intensive care unit. She did not have respiratory symptoms and remained on room air throughout her course in the neonatal intensive care unit. An echocardiogram on DOL 20 showed no evidence of pulmonary hypertension. On DOL 67, she presented with severe respiratory distress, shock, and cardiopulmonary arrest, and resuscitation included intubation, mechanical ventilation, oxygen, and nitric oxide. A cardiac catheterization demonstrated suprasystemic right heart pressures that were mildly responsive to inhaled nitric oxide. An open lung biopsy was diagnostic for ACDMPV. She remained mechanically ventilated and underwent bilateral lung transplantation on DOL 159. She developed bronchiolitis obliterans and died at 9 years of age.

Infant 5

This previously reported late preterm female infant born at 34 weeks of gestation was healthy at birth without respiratory symptoms.¹⁹ On DOL 24 she was briefly hospitalized for apnea that was attributed to gastroesophageal reflux and did not recur. On DOL 92, she was hospitalized for dehydration secondary to diarrhea and was found to be hypoxicemic. An echocardiogram demonstrated pulmonary hypertension. She was treated with supplemental oxygen via nasal cannula and sildenafil until DOL 273, when an open lung biopsy was diagnostic for ACDMPV. After the biopsy, she required venoarterial extracorporeal membrane oxygenation before transitioning to support from a paracorporeal lung assist

Table III. Histology of lung explants for infants with atypical presentations of ACDMPV

Infants	1	2	3	4	5	6
Deficient capillarization of alveoli	Mixed	Focal	Focal	Focal	Mixed	Mixed
Malposition of pulmonary veins	Patchy	Focal	Focal	Focal	Patchy	Patchy
Medial hypertrophy of small arteries and arterioles	Moderate to marked	Moderate	Moderate to marked	Moderate to marked	Moderate to marked	Moderate to marked
Lobular maldevelopment	Suggestive	Suggestive	Present	Present	Suggestive	Suggestive
Lymphangiectasis	Interlobular and BVBs	Interlobular and BVBs	Interlobular	Interlobular	Interlobular	Interlobular and BVBs
<i>FOXF1</i> sequencing	DNA not available	p.P49Q ³	No point mutations or deletions identified	p.P126L ³	No point mutations or deletions identified	1.5-Mb deletion upstream of <i>FOXF1</i> ¹⁷

Histologic assessment focused on areas of congested, noncollapsed lung, in which architecture and capillaries were well-visualized.

device.¹⁹ She underwent bilateral lung transplantation on DOL 286 and is alive at 6 years of age. Most recent (6 years) spirometry was normal (FEV₁ 96% of predicted, FVC 105% of predicted, and FEV₁/FVC 83%). The TLC was 1.90 L (94% of predicted), RV was 0.51 L (69% of predicted), and RV/TLC was 27%. The diffusing capacity of the lungs for carbon monoxide was normal.

Infant 6

This term female infant had transient tachypnea of the newborn with possible pneumonia.¹⁷ An echocardiogram revealed a patent ductus arteriosus without evidence of pulmonary hypertension. She was discharged from the neonatal intensive care unit on supplemental oxygen on DOL 17, which was continued until DOL 21. Over the next 5 months, she had poor weight gain and persistent retractions. She presented with respiratory distress and hypoxemia on DOL 212 during travel at high altitude. Cardiac catheterization demonstrated near systemic right heart pressures that were responsive to inhaled nitric oxide. Open lung biopsy was diagnostic of ACDMPV. She was gradually weaned off supplemental oxygen and nitric oxide and was discharged on DOL 249 on sildenafil and furosemide. On DOL 423, she developed an upper respiratory tract infection with coronavirus and progressive hypoxemic respiratory failure and required venovenous extracorporeal membrane oxygenation. She improved, was extubated, and received noninvasive positive pressure ventilation until bilateral lung transplantation on DOL 464. During the 3 months after the transplant, she had recurrent episodes of respiratory failure of unclear etiology and died at 18 months of age.

FOXF1 Sequencing and Assessment of CNVs

We obtained DNA from peripheral blood from 5 subjects (subjects 2-6). DNA was not available for subject 1. Two subjects had apparent nonmosaic missense variants in *FOXF1* (c.146C>A: p.P49Q [subject 2] and c.377C>T: p.P126L [subject 4])³ (Table III). Both variants are novel and not present in the Exome Aggregation Consortium database (exac.broadinstitute.org, Cambridge, MA)²⁰ and are predicted to be deleterious by *in silico* algorithms including SIFT, polyphen, LRT, mutation taster, GERP++, and PhyloP in ANNOVAR (annovar.openbioinformatics.org)²¹ and CADD (cadd.gs.washington.edu/).²² Subject 6 had an apparent nonmosaic 1.5-Mb CNV deletion mapping 306 kb upstream

to *FOXF1* that removed 26 kb of the proximal portion of the *FOXF1* enhancer region.¹⁷ Parental DNA sequencing for subjects 2 and 6 revealed that both the c.146C>A point mutation and the 1.5 Mb CNV deletion arose de novo. No point mutations or CNV deletions involving *FOXF1* were identified in subject 3 who had a sibling with ACDMPV, nor in subject 5.

Explant Histology

All 6 lung explants demonstrated the histologic features diagnostic of ACDMPV (Table III and Figure). The main findings of deficient capillarization and malpositioned pulmonary veins were focal or patchy as compared with infants with classic ACDMPV (Table IV). All explants demonstrated moderate to marked medial wall thickening of the small pulmonary arteries and arterioles consistent with the clinical histories of pulmonary hypertension. Lymphangiectasis was present in all explant specimens, including subjects 2 and 6, who were not mechanically ventilated at the time of transplantation. Although lobular maldevelopment with deficient alveolarization was diffuse and readily observed in all infants with classic ACDMPV, the explanted lungs of infants with atypical ACDMPV were more heterogeneous. Two of the explants (subjects 3 and 4) had focal areas with definite deficient alveolarization as well as other areas suggestive of maldevelopment. The other 4 atypical ACDMPV explants had focal areas suggestive of deficient alveolarization. Findings consistent with secondary remodeling were also present in the explanted lungs. There were no obvious differences in explant histopathology among infants with or without *FOXF1* point mutations or CNV deletions.

Discussion

Delayed presentations of ACDMPV after the neonatal period⁴⁻⁹ or with prolonged survival^{8,9,23,24} suggest biologically and developmentally diverse mechanisms contribute to disease presentation. In contrast with the classic neonatal presentation of ACDMPV, only 3 subjects (1, 2, and 6) had respiratory symptoms in the newborn period. Two infants (subjects 1 and 6) were treated with nasal cannula oxygen that was discontinued by 3 weeks of life, and then presented with fulminant symptoms at 3 and 7 months, respectively. The third infant (subject 2) had a persistent oxygen requirement and echocardiographic evidence of pulmonary hypertension that prompted diagnosis




Figure. A-D, Histology from infants with classic and atypical presentations of ACDMPV. Hematoxylin and eosin–stained sections of lung with low-power (10×) and high-power (40×) views of classic ACDMPV (A, B) and atypical ACDMPV (C, D). Congested areas were selected for better visualization of the capillaries. A, Malposition of veins adjacent to small arteries within BVBs and lobular maldevelopment with decreased alveolarization. B, Almost complete absence of capillary loops adjacent to alveolar epithelium (*), with fewer and displaced capillaries in septae (**). C, Malposition of veins adjacent to small arteries in BVBs. Compared with the histology of classic ACDMPV, decreased alveolarization is not readily apparent. D, Areas of both normal capillarization with capillaries adjacent to alveolar epithelium (arrow), and deficient capillarization with displaced capillaries in septae (**). a, artery; b, bronchus; v, vein.

tic lung biopsy at 1 month of age. Although this infant had the earliest presentation, biopsy, and diagnosis, he underwent lung transplant at the oldest age (DOL 633) and required the least respiratory support at the time of transplantation (supplemental nasal cannula oxygen and nitric oxide). His explant histology demonstrated focal findings, which may have contributed to his comparatively indolent course. The remaining 3 subjects had no significant respiratory symptoms within the first 2-3 months of life, including the infant with a family history of ACDMPV (subject 3). Because of the wide variability and timing of presentations, atypical ACDMPV should remain in the differential diagnosis of any infant with hypoxemia and idiopathic pulmonary hypertension.

The histopathologic characteristics of capillary dysplasia and misaligned pulmonary veins ranged from focal to patchy in the explanted lungs, but did not correlate with the age of fulminant presentation or the presence of *FOXF1* point mutations or CNV deletion. Although our study is limited in that explant histology may be confounded by differences in pretransplant treatment (mechanical ventilation, prolonged oxygen exposure) and chronologic age, the nonuniformity of histopathologic characteristics suggests that disruption of lung development in this disease is location specific and may be influenced by the local cellular and growth factor milieu. It is important to note that all 6 explants had areas of lung with normal capillary loops, a finding that illustrates the

Table IV. Histology from autopsies of infants with classic presentation of ACDMPV

Infant	1	2	3
Age at Presentation	Birth	Birth	1 day
Age at Death	15 days	9 days	8 days
Deficient capillarization of alveoli	Extensive	Extensive	Extensive
Malposition of pulmonary veins	Extensive	Extensive	Extensive
Medial hypertrophy of small arteries and arterioles	Mild	Mild	Mild
Lobular maldevelopment	Definite	Definite	Definite
Lymphangiectasis	Diffuse, interlobular	Diffuse, interlobular	Diffuse, interlobular

Histologic assessment focused on areas of congested, noncollapsed lung, in which architecture and capillaries were well visualized.

challenge of making a diagnosis of ACDMPV on a single specimen lung biopsy for patients with atypical presentations. Because point mutations or CNV deletions that involve *FOXF1* are present in approximately 80%-90% of infants with classic ACDMPV¹⁰ and 3 of 5 infants tested in our series, diagnostic sequencing of *FOXF1* may preclude the need for lung biopsy.²⁵ Failure to identify *FOXF1* point mutations or CNV deletions in 2 of the 5 subjects tested suggests that other genes may contribute to or modify the ACDMPV phenotype.¹⁰

All 6 infants in our series had clinical and histologic evidence for significant pulmonary hypertension. Medial wall hypertrophy, although present, was less pronounced among the 3 infants with classic ACDMPV (Table IV). It is unclear whether this difference reflects a primary process related to endothelial cell proliferation or is secondary to therapies or chronic/prolonged disruption of the pulmonary vascular bed. For 5 atypical ACDMPV infants, the severity of their pulmonary hypertension contributed to the eventual need for intensive medical and mechanical respiratory support before transplantation. Presumably, their pulmonary hypertension resulted from an anatomically fixed, decreased number of pulmonary capillaries within the alveolar epithelium, misaligned pulmonary veins, and abnormal lobular development. Although neonates with classic ACDMPV typically have transient but nonsustained responses to pulmonary vasodilators,¹ 3 atypical ACDMPV infants (subjects 2, 4, and 6) demonstrated a reduction in pulmonary resistance with inhaled nitric oxide administration during cardiac catheterization, and successful treatment of all 6 infants with pulmonary vasodilators suggests pharmacologically reversible components of pulmonary hypertension. However, our study was not specifically designed to determine the effects of these therapies thereby limiting this finding. The usefulness of these medications among infants with atypical ACDMPV compared with classic ACDMPV may reflect in part the heterogeneous nature of their disease or the diversity of the underlying biologic or developmental mechanisms.

Five infants in our series had chest CT scans that demonstrated findings of ILD with ground glass opacities and septal thickening. In contrast with infants with atypical ACDMPV, infants with idiopathic primary pulmonary hypertension typically are not hypoxic without a significant intracardiac shunt and usually do not have abnormalities of the pulmonary parenchyma on chest CT.²⁶ Infants with biallelic loss of function mutations in surfactant proteins (*SFTPB*, *ABCA3*) typically present with severe neonatal respiratory distress syndrome and have chest radiograph findings consistent with surfactant deficiency.²⁷ Infants with dominant point mutations in *SFTPC* or missense variants in *ABCA3* can present beyond the newborn period with childhood ILD and pulmonary hypertension, which when present, is associated with increased mortality.²⁸ The presentation of pulmonary venoocclusive disease and pulmonary capillary hemangiomatosis with hypoxemia, pulmonary hypertension, and abnormal CT scan results (patchy centrilobular pattern of ground glass opacities, pavement appearance to lobules) can make differentiation from ACDMPV potentially difficult. Owing to the wide variability and timing

of presentations, atypical ACDMPV should remain in the differential diagnosis of any infant with hypoxemia and idiopathic pulmonary hypertension including those with chest CT findings of ILD; clinical testing of *FOXF1* in these patients may be diagnostic.

Although lung transplantation is a recognized therapy for children with end-stage lung disease,²⁹ successful transplantation for ACDMPV is limited to 2 case reports.^{17,19} In a large international registry, the median survival of all children after lung transplant is 5.3 years, with infants having a slightly better median survival of 6.4 years.³⁰ The mortality and outcomes of the patients transplanted for ACDMPV in our series are comparable with infants and children transplanted for genetic disorders of surfactant metabolism at our institution.³¹ Prospective studies such as those being performed through the Childhood Interstitial Lung Disease Research Network are needed to identify genetic, therapeutic, or environmental factors that contribute to delayed presentation or prolonged survival without transplantation.³² ■

We thank the families for their participation in these research studies and the referring physicians. We thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison; a full list of contributing groups can be found at <http://exac.broadinstitute.org/about>.

Submitted for publication Jun 19, 2017; last revision received Sep 27, 2017; accepted Oct 12, 2017

Reprint requests: Jennifer A. Wambach, MD, MS, Edward Mallinckrodt Department of Pediatrics, Campus Box 8116, 660 S. Euclid Ave, St. Louis, MO 63110. E-mail: wambach_j@kids.wustl.edu

References

- Bishop NB, Stankiewicz P, Steinhorn RH. Alveolar capillary dysplasia. *Am J Respir Crit Care Med* 2011;184:172-9.
- Janney CG, Askin FB, Kuhn C 3rd. Congenital alveolar capillary dysplasia—an unusual cause of respiratory distress in the newborn. *Am J Clin Pathol* 1981;76:722-7.
- Sen P, Yang Y, Navarro C, Silva I, Szafranski P, Kolodziejska KE, et al. Novel *FOXF1* mutations in sporadic and familial cases of alveolar capillary dysplasia with misaligned pulmonary veins imply a role for its DNA binding domain. *Hum Mutat* 2013;34:801-11.
- Ahmed S, Ackerman V, Faught P, Langston C. Profound hypoxemia and pulmonary hypertension in a 7-month-old infant: late presentation of alveolar capillary dysplasia. *Pediatr Crit Care Med* 2008;9:e43-6.
- Michalsky MP, Arca MJ, Groenman F, Hammond S, Tibboel D, Caniano DA. Alveolar capillary dysplasia: a logical approach to a fatal disease. *J Pediatr Surg* 2005;40:1100-5.
- Shankar V, Haque A, Johnson J, Pietsch J. Late presentation of alveolar capillary dysplasia in an infant. *Pediatr Crit Care Med* 2006;7:177-9.
- Abdallah HI, Karmazin N, Marks LA. Late presentation of misalignment of lung vessels with alveolar capillary dysplasia. *Crit Care Med* 1993;21:628-30.
- Kodama Y, Tao K, Ishida F, Kawakami T, Tsuchiya K, Ishida K, et al. Long survival of congenital alveolar capillary dysplasia patient with NO inhalation and epoprostenol: effect of sildenafil, beraprost and bosentan. *Pediatr Int* 2012;54:923-6.
- Ito Y, Akimoto T, Cho K, Yamada M, Tanino M, Dobata T, et al. A late presenter and long-term survivor of alveolar capillary dysplasia with misalignment of the pulmonary veins. *Eur J Pediatr* 2015;174:1123-6.
- Szafranski P, Gambin T, Dharmadhikari AV, Akdemir KC, Jhangani SN, Schuette J, et al. Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veins. *Hum Genet* 2016;135:569-86.

11. Sen P, Thakur N, Stockton DW, Langston C, Bejjani BA. Expanding the phenotype of alveolar capillary dysplasia (ACD). *J Pediatr* 2004;145:646-51.
12. Langston C. Misalignment of pulmonary veins and alveolar capillary dysplasia. *Pediatr Pathol* 1991;11:163-70.
13. Deutsch GH, Young LR, Deterding RR, Fan LL, Dell SD, Bean JA, et al. Diffuse lung disease in young children: application of a novel classification scheme. *Am J Respir Crit Care Med* 2007;176:1120-8.
14. Lally KP, Breaux CW Jr. A second course of extracorporeal membrane oxygenation in the neonate—is there a benefit? *Surgery* 1995;117:175-8.
15. Melly L, Sebire NJ, Malone M, Nicholson AG. Capillary apposition and density in the diagnosis of alveolar capillary dysplasia. *Histopathology* 2008;53:450-7.
16. Khan MS, Heinle JS, Samayoa AX, Adachi I, Schecter MG, Mallory GB, et al. Is lung transplantation survival better in infants? Analysis of over 80 infants. *J Heart Lung Transplant* 2013;32:44-9.
17. Szafranski P, Dharmadhikari AV, Wambach JA, Towe CT, White FV, Grady RM, et al. Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins. *Am J Med Genet A* 2014;164A:2013-9.
18. Langston C, Dishop MK. Diffuse lung disease in infancy: a proposed classification applied to 259 diagnostic biopsies. *Pediatr Dev Pathol* 2009;12:421-37.
19. Boston US, Fehr J, Gazit AZ, Eghtesady P. Paracorporeal lung assist device: an innovative surgical strategy for bridging to lung transplant in an infant with severe pulmonary hypertension caused by alveolar capillary dysplasia. *J Thorac Cardiovasc Surg* 2013;146:e42-3.
20. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285-91.
21. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38:e164.
22. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;46:310-5.
23. Licht C, Schickendantz S, Sreeram N, Arnold G, Rossi R, Vierzig A, et al. Prolonged survival in alveolar capillary dysplasia syndrome. *Eur J Pediatr* 2004;163:181-2.
24. Shehata BM, Abramowsky CR. Alveolar capillary dysplasia in an infant with trisomy 21. *Pediatr Dev Pathol* 2005;8:696-700.
25. Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, Castile RG, et al. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. *Am J Respir Crit Care Med* 2013;188:376-94.
26. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. *Circulation* 2015;132:2037-99.
27. Wambach JA, Casey AM, Fishman MP, Wegner DJ, Wert SE, Cole FS, et al. Genotype-phenotype correlations for infants and children with ABCA3 deficiency. *Am J Respir Crit Care Med* 2014;189:1538-43.
28. Fan LL, Dishop MK, Galambos C, Askin FB, White FV, Langston C, et al. Diffuse lung disease in biopsied children 2 to 18 years of age. Application of the chILD classification scheme. *Ann Am Thorac Soc* 2015;12:1498-505.
29. Palomar LM, Noguee LM, Sweet SC, Huddleston CB, Cole FS, Hamvas A. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. *J Pediatr* 2006;149:548-53.
30. Goldfarb SB, Benden C, Edwards LB, Kucheryavaya AY, Dipchand AI, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: eighteenth official pediatric lung and heart-lung transplantation report—2015; focus theme: early graft failure. *J Heart Lung Transplant* 2015;34:1255-63.
31. Eldridge WB, Zhang Q, Faro A, Sweet SC, Eghtesady P, Hamvas A, et al. Outcomes of lung transplantation for infants and children with genetic disorders of surfactant metabolism. *J Pediatr* 2017;184:157-64, e2.
32. Young LR, Trapnell BC, Mandl KD, Swarr DT, Wambach JA, Blaisdell CJ. Accelerating scientific advancement for pediatric rare lung disease research. Report from a national institutes of health-NHLBI workshop, September 3 and 4, 2015. *Ann Am Thorac Soc* 2016;13:385-93.

Table I. Published reports of infants with delayed presentation of ACDMPV

Ages at presentation	EGA (wk)	Sex	Family history	Neonatal symptoms	Additional anomalies	Pulmonary hypertension medications	Histology	FOXF1 sequencing	Outcome	Authors
5 weeks	Term	Female	Male sibling with ACDMPV	Cyanosis and respiratory distress after birth, episodes of tachypnea and lethargy, discharged home at 10 days	None	Norepinephrine, intrapulmonary prostaglandin E ₁	Capillaries of alveolar septa did not reach alveolar epithelium, muscularization of peripheral arterial branches, misalignment of the pulmonary veins, dilated lymphatics	NR	Death at 5 weeks	Abdallah et al ⁷
4 weeks	NR	NR	NR	None	None	iNO, prostacyclin	Alveolar capillary dysplasia	NR	Death during hospital course	Michalsky et al ⁵
7 weeks	Term	Female	NR	None	Aganglionosis of colon	Dopamine, milrinone, iNO	Malalignment of pulmonary veins, paucity of alveolar capillaries, prominent muscularization of arterioles, thickening of alveolar septa, widened interstitium	NR	Death at 4 months	Shankar et al ⁶
7 months	Term	Female	NR	Cyanotic episode after birth, received 0.1 L/min oxygen for 13 days, mild pulmonary hypertension on echocardiogram	Small ventricular septal defect	Dopamine, milrinone, iNO	Small pulmonary lobules, few normally positioned capillaries, muscularized small arterioles, misalignment of the pulmonary veins, patchy lymphatic dilation	NR	Death at 7-8 months	Ahmed et al ⁴
3 months	Term	Male	Negative	None	Muscular ventricular septal defect, small atrial septal defect	Milrinone, iNO, pulse methylprednisolone, IVIG, sildenafil, prostacyclin, bosentan, supplemental oxygen	Misalignment of the pulmonary veins, thick alveolar walls with pool alveolar capillary development, several normal alveolar walls	c.899Tdel p.L300Rfs*79 <i>de novo</i>	Alive at 38 months per manuscript, alive at 62 months of age*	Ito et al ⁹

EGA, Estimated gestational age; iNO, inhaled nitric oxide; IVIG, intravenous immunoglobulin; NR, not reported.

*Personal communication: Dr Satoru Kumaki January 2017.